Brian Goff, Agios CEO

Agios to take over Al­ny­lam’s pre­clin­i­cal siR­NA blood dis­or­der as­set in a deal worth $147.5M

Agios and Al­ny­lam have agreed on an ex­clu­sive glob­al li­cens­ing deal worth $147.5 mil­lion for Agios to take over the de­vel­op­ment and com­mer­cial­iza­tion of a poly­cythemia ve­ra pre­clin­i­cal siR­NA can­di­date.

Agios is pay­ing $17.5 mil­lion up­front, with Al­ny­lam re­ceiv­ing up to $130 mil­lion for de­vel­op­ment and reg­u­la­to­ry mile­stone pay­ments, on top of sales mile­stones and tiered roy­al­ties, ac­cord­ing to a press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.